(1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethanol p-toluenesulfonate | 1173089-00-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethanol p-toluenesulfonate
• 英文别名: [(1S,2S,4R)-spiro[bicyclo[2.2.1]heptane-3,1'-cyclopropane]-2-yl]methyl 4-methylbenzenesulfonate
• CAS: 1173089-00-3
• 化学式: C₁₇H₂₂O₃S
• 分子量: 306.426
• InChiKey: OJDVODHUGQUMCK-LZWOXQAQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethanol p-toluenesulfonate 、 4-（2-酮酸-1-苯并咪唑）哌啶 在 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 24.0h， 以39%的产率得到1-{[(1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
  参考文献：
  名称：

  Identification of an Orally Active Opioid Receptor-like 1 (ORL1) Receptor Antagonist 4-{3-[(2R)-2,3-Dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1′-cyclopropan]-3-ylmethyl]piperidine as Clinical Candidate

  摘要：

  Our efforts to optimize prototype opioid receptor-like I (ORL1) antagonist 1 led to the discovery of 4-{3-[(2R)-2, 3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine 10. 10 showed potent ORL1 antagonistic activity, excellent selectivity over other opioid receptors, and in vivo efficacy after oral dosing. Currently clinical trials of 10 are underway.

  DOI：

  10.1021/jm900581g
• 作为产物：
  描述：

  (1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethanol 、 对甲苯磺酰氯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 氯仿 为溶剂， 以100%的产率得到(1S,3R,6S)-2,1'-spirocyclopropane(bicyclo[2.2.1]heptane)-1'-norbornylmethanol p-toluenesulfonate
  参考文献：
  名称：

  Identification of an Orally Active Opioid Receptor-like 1 (ORL1) Receptor Antagonist 4-{3-[(2R)-2,3-Dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1′-cyclopropan]-3-ylmethyl]piperidine as Clinical Candidate

  摘要：

  Our efforts to optimize prototype opioid receptor-like I (ORL1) antagonist 1 led to the discovery of 4-{3-[(2R)-2, 3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine 10. 10 showed potent ORL1 antagonistic activity, excellent selectivity over other opioid receptors, and in vivo efficacy after oral dosing. Currently clinical trials of 10 are underway.

  DOI：

  10.1021/jm900581g

文献信息

• Identification of an Orally Active Opioid Receptor-like 1 (ORL1) Receptor Antagonist 4-{3-[(2<i>R</i>)-2,3-Dihydroxypropyl]-2-oxo-2,3-dihydro-1<i>H</i>-benzimidazol-1-yl}-1-[(1<i>S</i>,3<i>S</i>,4<i>R</i>)-spiro[bicyclo[2.2.1]heptane-2,1′-cyclopropan]-3-ylmethyl]piperidine as Clinical Candidate
  作者：Atsushi Satoh、Takeshi Sagara、Hiroki Sakoh、Masaya Hashimoto、Hiroshi Nakashima、Tetsuya Kato、Yasuhiro Goto、Sayaka Mizutani、Tomoko Azuma-Kanoh、Takeshi Tani、Shoki Okuda、Osamu Okamoto、Satoshi Ozaki、Yoshikazu Iwasawa、Hisashi Ohta、Hiroshi Kawamoto

  DOI：10.1021/jm900581g

  日期：2009.7.23

  Our efforts to optimize prototype opioid receptor-like I (ORL1) antagonist 1 led to the discovery of 4-3-[(2R)-2, 3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine 10. 10 showed potent ORL1 antagonistic activity, excellent selectivity over other opioid receptors, and in vivo efficacy after oral dosing. Currently clinical trials of 10 are underway.